187 related articles for article (PubMed ID: 36051980)
1. Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
Ramphall S; Rijal S; Prakash V; Ekladios H; Mulayamkuzhiyil Saju J; Mandal N; Kham NI; Shahid R; Naik SS; Venugopal S
Cureus; 2022 Aug; 14(8):e28485. PubMed ID: 36051980
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.
Gao Y; Jin H
Ther Adv Chronic Dis; 2022; 13():20406223221097331. PubMed ID: 35634570
[TBL] [Abstract][Full Text] [Related]
3. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.
Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
J Am Acad Dermatol; 2013 Dec; 69(6):1033-1042.e1. PubMed ID: 24028907
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.
Gao Y; Jin H
Dermatol Ther; 2021 Sep; 34(5):e15051. PubMed ID: 34197012
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.
Seguí M; Llamas-Velasco M
Front Med (Lausanne); 2022; 9():993515. PubMed ID: 36569162
[TBL] [Abstract][Full Text] [Related]
6. Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.
Kofler K; Strölin A; Geiger V; Kofler L
J Cutan Med Surg; 2021 Sep; 25(5):504-510. PubMed ID: 33779349
[TBL] [Abstract][Full Text] [Related]
7. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
Ishibashi M; Miyamoto J; Nagasaka T; Chen KR
Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
[TBL] [Abstract][Full Text] [Related]
8. Penile Livedoid Vasculopathy: First Reported Case.
Hallak A; Bennett W; Tanbir MA; Donthamsetty SR; Vincent B
Case Rep Vasc Med; 2023; 2023():6920383. PubMed ID: 37440957
[TBL] [Abstract][Full Text] [Related]
9. Ulcerative livedoid vasculopathy responding to clopidogrel.
Kunzler E; Chong BF
JAAD Case Rep; 2018 Mar; 4(2):203-205. PubMed ID: 29892667
[No Abstract] [Full Text] [Related]
10. Botulinum toxin-A: A novel treatment for livedoid vasculopathy.
Crotty AM; Eubanks BN; Katana VG; Wright KT
JAAD Case Rep; 2022 Nov; 29():27-29. PubMed ID: 36186404
[No Abstract] [Full Text] [Related]
11. Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.
Zhao C; Yu M; Cheng X; Li S; Feng S
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38287670
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.
Monshi B; Posch C; Vujic I; Sesti A; Sobotka S; Rappersberger K
J Am Acad Dermatol; 2014 Oct; 71(4):738-44. PubMed ID: 25022849
[TBL] [Abstract][Full Text] [Related]
13. Atrophie blanche: is it associated with venous disease or livedoid vasculopathy?
Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
Adv Skin Wound Care; 2014 Nov; 27(11):518-24; quiz 525-6. PubMed ID: 25325229
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of livedoid vasculopathy with rivaroxaban.
Evans JM; Jensen JD; Sami N
JAAD Case Rep; 2015 Nov; 1(6):340-1. PubMed ID: 27051773
[No Abstract] [Full Text] [Related]
15. Livedoid vasculopathy - A diagnostic and therapeutic challenge.
Burg MR; Mitschang C; Goerge T; Schneider SW
Front Med (Lausanne); 2022; 9():1012178. PubMed ID: 36262273
[TBL] [Abstract][Full Text] [Related]
16. Clinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.
Shah SR; Vyas HR; Doshi YJ; Shah BJ
Indian Dermatol Online J; 2022; 13(6):771-774. PubMed ID: 36386750
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Multicenter Trial With Rivaroxaban in the Treatment of Livedoid Vasculopathy Assessing Pain on a Visual Analog Scale.
Drabik A; Hillgruber C; Goerge T
JMIR Res Protoc; 2014 Dec; 3(4):e73. PubMed ID: 25500152
[TBL] [Abstract][Full Text] [Related]
19. Treatment for Livedoid Vasculopathy: A Systematic Review.
Micieli R; Alavi A
JAMA Dermatol; 2018 Feb; 154(2):193-202. PubMed ID: 29141075
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab in the Treatment of Recalcitrant Livedoid Vasculopathy.
Bhatt DM; Bhamburkar S; Madke B; Jangid SD; Khan A
Cureus; 2023 Dec; 15(12):e50053. PubMed ID: 38186477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
